MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...

GLP-1 weight-loss drugs like Ozempic and Zepbound might help protect people from health risks related to sleep apnea, ...

Chong Kun Dang launches Archela to focus on new drug development Chong Kun Dang spins off Archela to streamline development ...

Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases ...

Doctors and pharmaceutical experts have raised growing concerns about the shortages in recent months. The American Medical ...

Eli Lilly is expected to present third-quarter results on Oct. 30 after the market opens. Wall Street analysts will be ...

A meeting will be held to elect new board members following a disagreement between the board and its majority shareholder.

The approval was based on the SOUL trial, which evaluated oral semaglutide in adults 50 years and older with T2DM and established CV disease and/or chronic kidney disease.

Clinical Director of the National Institute of Drug Abuse Dr. Lorenzo Leggio, said GLP-1 drugs' effect on the brain can help ...

Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q3 2025 Earnings Call October 22, 2025 4:30 PM EDT Welcome to the Viking Therapeutics Third Quarter 2025 Financial Results Conference Call. [Operator ...

A real weight loss drug, called retatrutide, is currently being developed by pharmaceutical giant Eli Lilly, but there has ...